# US 2025/0152555 A1 · Pharmaceutical Composition for Preventing or Treating Triple-Negative Breast Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152555 A1
- Document ID: US20250152555A1
- Status: Published application
- Kind: A1
- Application number: 18/722,507
- Filed: 2022-12-30
- Published: 2025-05-15
- Earliest claimed: 2021-12-30
- Assignees: Daewoong Pharmaceutical Co., Ltd.
- Applicants: Daewoong Pharmaceutical Co., Ltd.
- Inventors: Ahreum Kwon; Kwon Jo Lim; Ji Duck Kim; Joon Seok Park
- Web page: https://patentgrep.com/patent/US20250152555A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition comprising a compound represented by Chemical Formula 1 described in the present specification, or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent. The pharmaceutical composition can be usefully used for preventing or treating triple-negative breast cancer.

## Claims

### Claim 1

A method for preventing or treating triple-negative breast cancer in a subject in need thereof, comprising administering to the subject:
a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and
a chemotherapeutic agent:

### Claim 2 (depends on 1)

The method according to claim 1, wherein:
the chemotherapeutic agent is Doxorubicin, or docetaxel.

### Claim 3 (depends on 1)

The method according to claim 1, wherein:
a molar ratio of the compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the chemotherapeutic agent is 5:1 or more.

### Claim 4 (depends on 1)

The method according to claim 1, wherein:
the chemotherapeutic agent is Doxorubicin, and
the molar ratio of the compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and Doxorubicin is 9.5:1 or more and 11:1 or less.

### Claim 5 (depends on 1)

The method according to claim 1, wherein:
the chemotherapeutic agent is docetaxel, and
the molar ratio of the compound represented by Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and docetaxel is 1000:1 or more.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein:
the triple-negative breast cancer is caused by V-ATPase overexpression.
